0.4054
前日終値:
$0.488
開ける:
$0.4519
24時間の取引高:
430.84K
Relative Volume:
0.57
時価総額:
$17.29M
収益:
$45.91M
当期純損益:
$-4.62M
株価収益率:
-2.8916
EPS:
-0.1402
ネットキャッシュフロー:
$-21.51M
1週間 パフォーマンス:
-47.55%
1か月 パフォーマンス:
-46.90%
6か月 パフォーマンス:
-51.29%
1年 パフォーマンス:
-82.45%
Equillium Inc Stock (EQ) Company Profile
EQ を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
EQ
Equillium Inc
|
0.4054 | 17.29M | 45.91M | -4.62M | -21.51M | -0.1402 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Equillium Inc Stock (EQ) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2021-10-29 | 再開されました | Stifel | Buy |
2021-09-15 | 開始されました | Cantor Fitzgerald | Overweight |
2020-07-14 | 繰り返されました | H.C. Wainwright | Buy |
2020-07-10 | 再開されました | Stifel | Buy |
2019-02-22 | 開始されました | SVB Leerink | Outperform |
Equillium Inc (EQ) 最新ニュース
Leerink Partners Downgrades Equillium (LSE:0A4D) - Nasdaq
Equillium stock tumbles on Phase 3 study results - Investing.com
Leerink Partners Downgrades Equillium to Market Perform From Outperform, Adjusts Price Target to $1 From $3 - Marketscreener.com
Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease - BioSpace
Equillium Reports 2024 Financials and Clinical Milestones - TipRanks
Equillium (EQ) Surprises with Smaller Q4 Loss Amid Revenue Dip - GuruFocus.com
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Equillium stock hits 52-week low at $0.49 amid market challenges By Investing.com - Investing.com South Africa
Equillium Seeks Accelerated Approval For GVHD Drug Despite Primary Endpoint Miss - Scrip
Equillium reports mixed results in aGVHD study, seeks FDA fast track By Investing.com - Investing.com South Africa
Equillium pushes for breakthrough status despite missing primary endpoint - Yahoo Finance
Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results - Benzinga
Equillium stock hits 52-week low at $0.49 amid market challenges - Investing.com Australia
Equillium fails to improve complete response in GVHD treatment study - Seeking Alpha
Nasdaq Down Over 100 Points; US Initial Jobless Claims Fall - Benzinga
Equillium drug fails main trial goal but shows longer-term promise - The Pharma Letter
Equillium, Inc. Announces Results of the Phase 3 Equator Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease - Marketscreener.com
Equillium reports mixed results in aGVHD study, seeks FDA fast track - Investing.com India
Equillium Reports Phase 3 Results Of Itolizumab For Acute Graft-Versus-Host Disease - Marketscreener.com
Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights - Bluefield Daily Telegraph
Breakthrough GVHD Treatment: New Drug Extends Response Duration by 4.7x in Phase 3 Trial - StockTitan
Equillium (EQ) to Release Quarterly Earnings on Monday - Defense World
Equillium Stock Price, Quotes and Forecasts - Benzinga
SHAREHOLDER ALERT: Weiss Law Reminds EQ, IMGO, MTCR, and OPNT Shareholders About Its Ongoing Investigations - Marketscreener.com
Equillium stock rallies 26% on itolizumab study data - MSN
Here's Why Equillium (EQ) Is a Great 'Buy the Bottom' Stock Now - Zacks Investment Research
Equillium, Inc.'s (NASDAQ:EQ) Price Is Right But Growth Is Lacking After Shares Rocket 27% - Simply Wall St
Leerink Partnrs Forecasts Stronger Earnings for Equillium - Defense World
Equillium (EQ) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Equillium (EQ) Shows Fast-paced Momentum But Is Still a Bargain Stock - Nasdaq
Healthy Upside Potential: Equillium Inc (EQ) - SETE News
Equillium Inc (EQ) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
Equillium reports positive Phase 2 ulcerative colitis study data - MSN
why Borr Drilling Ltd [BORR] is a Good Choice for Investors After New Price Target of $5.23 - The DBT News
Callan JMB Inc [CJMB] gain 54.15% so far this year. What now? - The DBT News
Wall Street Analyst Resumed Equillium Inc [EQ]. What else is Wall St. saying - The DBT News
Equillium Inc [EQ] Shares Rise 33.03 % on Thursday - Knox Daily
What to expect from Equillium Inc’s (EQ) current quarter earnings? - US Post News
Insider Selling: Nachiappan Venkatachalam, Arhaus Inc [ARHS] Chief Information Officer divested 6,460 shares - Knox Daily
10% Owner HGC Next Inv LLC acquire 11,690,909 shares of NextDecade Corporation [NEXT] - Knox Daily
CuriosityStream And 2 Other Promising Penny Stocks On US Exchange - Simply Wall St
Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis - StreetInsider.com
Equillium and Biocon announce positive data from Phase 2 study evaluating Itolizumab for ulcerative colitis - Indian Pharma Post
UDR Inc (UDR) Q4 2024 Earnings Call Highlights: Strong Occupancy and Strategic Growth Plans ... - Yahoo Finance UK
Biocon, Equillium announce positive data from Phase 2 Study evaluating Itolizumab for Ulcerative Colitis - Medical Dialogues
Stocks to Watch, Feb 7: Biocon, SBI, LIC, M&M, Bharti Airtel, Ola Electric - Business Standard
Equillium Reports Positive Phase 2 Results for Itolizumab in Ulcerative Colitis, Shares Surge - Yahoo Finance
Equillium reports positive Phase 2 ulcerative colitis study data By Investing.com - Investing.com South Africa
Equillium Announces Positive Data from Phase 2 Study Evaluating - GuruFocus.com
Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis – Company AnnouncementFT.com - Financial Times
Lugman Group withdraws from purchase of “Industrial Park Fechenheim” - Yahoo Finance UK
Equillium Inc (EQ) 財務データ
収益
当期純利益
現金流量
EPS
Equillium Inc (EQ) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Keyes Jason A | Chief Financial Officer |
Nov 14 '24 |
Sale |
0.70 |
10,000 |
7,000 |
47,720 |
大文字化:
|
ボリューム (24 時間):